Chemicals & Advanced Materials Global On demand · 24-48h

Global Polydeoxyribonudeotide (PDRN) Market Strategic Research Report

Global Polydeoxyribonudeotide (PDRN) Market Strategic Resear…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Polydeoxyribonudeotide (PDRN) Market
$1032025
31.7%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Powder, Solution

By Application: Mesotherapy, Bone Injection & Dermal Fillers, Pharmaceutical, Cosmetic, Wound Healing Products and Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: HTL Biotechnology, ReaLi Tide Biological, PharmaResearch Co., Ltd., Humedix, Ruijiming Biological, Bloomage Biotech, HENGYU BIOPH, Mastelli, Dongkook, BR PHARM, BNC Global, BMI KOREA, BNF Solution, Nanjing Letop Biotechnology, Topscience Biotech, Freda Biotechnology, Shebah Biotech, APR Corporation, Kolmar Korea, PORIBIO INC.

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 143 pages
Market size 2025
$103
Million USD
Forecast CAGR
31.7%
2025-2032
Forecast 2032
$707.8
Projected
区域
5
Asia Pacific · Latin America · MEA · Europe · North America

概述

Scope of the Report

The global Polydeoxyribonudeotide (PDRN) market size is predicted to grow from US$ 103 million in 2025 to US$ 694 million in 2032; it is expected to grow at a CAGR of 31.7% from 2026 to 2032.

PDRN is deoxyribonucleic acid(DNA) product, mainly comes from semen and roe of fish, rapidly repair injured scars. It can promote the collagen synthesis on the cell surface, reverse aging signs. PDRN is the excellent skin repair product widely used for both high-end beauty products and medical products. Strong functions of anti-radiation and shrinking pores, make skin appears brightly and elastically.

Polydeoxyribonucleotide (PDRN) and polynucleotide (PN) are regenerative materials extracted from the regenerative cell (sperm and testicle) gene segment (DNA) of salmon or trout. The molecular sizes of PDRN and PN are different (PN is bigger) and they are safe biogenic substances approved by the Ministry of Food and Drug Safety. PDRN are often used in pharmaceuticals for tissue regeneration and cornea regeneration as well as treatment and tissue restoration of wounds. PN is often used for medical devices (tissue regeneration) for skin regeneration, articular cartilage regeneration, and osteogenic tissues.

Both PDRN and PN are included in the report.

As a product of regenerative medicine, PDRN can synthesize DNA from damaged or hypoxic tissues, activate the regeneration of endogenous growth factors such as FGF, IGF, and EGF, accelerate cell metabolism, and improve skin repair and regeneration capabilities. The fiber network full of collagen and elastin can achieve skin rejuvenation, improve skin microenvironment, increase skin thickness, etc., so as to achieve the effect of improving problem skin.

The PDRN market has shown a significant growth trend in recent years, mainly driven by the field of regenerative medicine and tissue engineering, as well as the field of aesthetics. Demand for innovative solutions in medical fields such as wound healing, dermatology, orthopedics is driving the demand for PDRN products and therapies.

In terms of product types, freeze-dried powder occupies an important position, dominated with 65% market share in 2024, preferred for stability and versatility in pharmaceuticals and cosmetics. While PDRN Solutions are growing demand in injectables (e.g., mesotherapy), especially in Korea’s "salmon needle" treatments. Expected to surge due to ease of clinical applicationAt the same time, in terms of application, the share of Medical Aesthetics (Mesotherapy) in 2024 is about 32%, used in "regenerative hydrogels" for collagen synthesis and anti-inflammatory effects.

The major global manufacturers of Polydeoxyribonudeotide (PDRN) include HTL Biotechnology, Ruijiming Biological, PharmaResearch Co., Ltd., Humedix, ReaLi Tide Biological, HENGYU BIOPH, Mastelli, Dongkook, BR PHARM, BMI KOREA, BNF Solution, etc. In 2024, the world's top three vendors accounted for approximately 56% of the revenue.

As a new type of regenerative material, PDRN has multiple activities such as promoting skin damage repair, anti-inflammatory, promoting angiogenesis, improving tissue microcirculation, etc. It has broad application prospects in the fields of medical devices, medicine, cosmetics, health foods, daily chemical products, medical cosmetology, etc. In the future, with the rise of medical beauty consumption and the expansion of application fields, the scale of the PDRN market will further expand. The PDRN market is poised for explosive growth, anchored by Asia-Pacific’s dominance (Korea/China) and diversification into cosmetics/wound care. Key developments include China’s regulatory openings, plant-based innovations, and the rise of "regenerative aesthetics."

This report presents a comprehensive overview of the global Polydeoxyribonudeotide (PDRN) market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Powder
  • Solution

Segment by Application

  • Mesotherapy
  • Bone Injection & Dermal Fillers
  • Pharmaceutical
  • Cosmetic
  • Wound Healing Products and Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Polydeoxyribonudeotide (PDRN) market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Mesotherapy, Bone Injection & Dermal Fillers, Pharmaceutical evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Polydeoxyribonudeotide (PDRN) Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 31.7%
Regional growth momentum
Market share by segment
Key metrics
Base value
$103
2025
Forecast
$707.8
2032
CAGR
31.7%
2025–2032
区域
5
global
Key companies
HTL BiotechnologyReaLi Tide BiologicalPharmaResearch Co., Ltd.HumedixRuijiming BiologicalBloomage BiotechHENGYU BIOPHMastelli
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
PowderSolution
By Application
MesotherapyBone Injection & Dermal FillersPharmaceuticalCosmeticWound Healing Products and Others

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Powder
  • 3.1.3 Solution
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Mesotherapy
  • 4.1.3 Bone Injection & Dermal Fillers
  • 4.1.4 Pharmaceutical
  • 4.1.5 Cosmetic
  • 4.1.6 Wound Healing Products and Others
  • 4.1.7 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 HTL Biotechnology
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 ReaLi Tide Biological
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 PharmaResearch Co., Ltd.
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Humedix
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Ruijiming Biological
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Bloomage Biotech
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 HENGYU BIOPH
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Mastelli
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Dongkook
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 BR PHARM
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 BNC Global
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 BMI KOREA
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 BNF Solution
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Nanjing Letop Biotechnology
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Topscience Biotech
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Freda Biotechnology
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Shebah Biotech
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 APR Corporation
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Kolmar Korea
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 PORIBIO INC.
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Polydeoxyribonudeotide (PDRN) market?
The global Polydeoxyribonudeotide (PDRN) market is estimated at US$ 103 million in 2025 (base year) and is projected to reach US$ 694 million by 2032.
How fast is the Polydeoxyribonudeotide (PDRN) market expected to grow?
The market is expected to grow at a CAGR of 31.7% from 2026 to 2032, expanding from US$ 103 million in 2025 to US$ 694 million in 2032, roughly 6.7 times its base-year value.
What does the Polydeoxyribonudeotide (PDRN) market cover?
PDRN is deoxyribonucleic acid(DNA) product, mainly comes from semen and roe of fish, rapidly repair injured scars. It can promote the collagen synthesis on the cell surface, reverse aging signs. PDRN is the excellent skin repair product widely used for both high-end beauty products and medical products.
What are the main segments of the Polydeoxyribonudeotide (PDRN) market by type?
By type, the market is segmented into Powder and Solution.
Which applications drive demand in the Polydeoxyribonudeotide (PDRN) market?
Key applications covered include Mesotherapy, Bone Injection & Dermal Fillers, Pharmaceutical, Cosmetic and Wound Healing Products and Others.
Who are the key players in the Polydeoxyribonudeotide (PDRN) market?
Key players profiled include HTL Biotechnology, ReaLi Tide Biological, PharmaResearch Co., Humedix, Ruijiming Biological, Bloomage Biotech, HENGYU BIOPH and Mastelli, among 20 companies covered in total.
Which regions and countries are covered for Polydeoxyribonudeotide (PDRN)?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Polydeoxyribonudeotide (PDRN) market?
The PDRN market has shown a significant growth trend in recent years, mainly driven by the field of regenerative medicine and tissue engineering, as well as the field of aesthetics.
Who should buy the Polydeoxyribonudeotide (PDRN) market report?
The report is intended for manufacturers and solution providers, distributors and end users in Mesotherapy, Bone Injection & Dermal Fillers and Pharmaceutical, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Polydeoxyribonudeotide (PDRN) market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from US$3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.